U.S. markets closed

Apellis Pharmaceuticals, Inc. (APLS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
58.32-2.77 (-4.53%)
At close: 04:00PM EDT
55.41 -2.91 (-4.99%)
After hours: 05:07PM EDT

Apellis Pharmaceuticals, Inc.

100 Fifth Avenue
Waltham, MA 02451
United States
617 977 5700

Full Time Employees476

Key Executives

NameTitlePayExercisedYear Born
Dr. Cedric Francois M.D., Ph.D.Co-Founder, Pres, CEO & Director969.54k3.65M1972
Dr. Pascal Deschatelets Ph.D.Co-Founder & Chief Scientific Officer609.85k1.44M1970
Dr. Federico Grossi M.D., Ph.D.Co-Founder & Chief Medical Officer578.01k1.79M1974
Mr. Alec Machiels J.D., MBACo-Founder & Director72.5kN/A1973
Mr. Timothy E. SullivanCFO & Treasurer630.17k1.96M1971
Mr. Adam J. TownsendChief Commercial Officer602.69kN/A1977
Ms. Nur NicholsonChief Technical Operations OfficerN/AN/AN/A
Mr. James G. Chopas CPAVP, Corp. Controller & Chief Accounting OfficerN/AN/A1966
Ms. Meredith KayaSr. VP, Investor Relations & Strategic Fin.N/AN/AN/A
Mr. David O. WatsonGen. CounselN/AN/A1973
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Corporate Governance

Apellis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of September 1, 2022 is 8. The pillar scores are Audit: 7; Board: 8; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.